Looking Ahead in Biopharma: 2024

Insight Exchange by L.E.K. Consulting

Today we venture into the crucial landscape of biopharma, anticipating the trends and challenges that will shape the industry in 2024.

This episode aims to provide insights into the potential changes and advancements in the biopharmaceutical industry. It delves into various topics, including the use of artificial intelligence (AI) in drug discovery and different functional areas alongside challenges and strategies for enhancing commercial models with digital technologies. It also covers the impact of U.S. legislation on pharmacy operations, with a particular focus on maximum fair prices for prescription drugs and potentially greater transparency of the pharmacy benefit manager function.

Key points/topics covered:

• Impact of legislation on pharmacy operations
• Advancements and implications of AI in drug discovery and biopharma
• Challenges of, and strategies for enhancing commercial models with digital technologies
• Developments in cell therapy, gene therapy and advanced modalities
• Biopharma market correction, financing and M&A

Interested in learning more? Read our Executive Insights, Looking Ahead in Biopharma: 2024.

Connect with our experts on LinkedIn:
Peter Rosenorn, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/peterrosenorn/
Alex Guth, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/alex-guth-phd/
Matt Mancuso, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/matthewmancusophd/
Jenny Mackey, Healthcare Insights Center Director, L.E.K. Consulting: https://www.linkedin.com/in/jenny-mackey-2a594a62/

Visit L.E.K. Consulting at https://www.lek.com/